Mon - Fri 9AM-5PM +1-407-776-9217

Diverse Pharma


Cannabinoids have exciting potential as tomorrow’s greatest medicines. Today, however, asking the right questions about how and why they work is critical.

Diverse Pharma is working to understand the potential of these compounds by uncovering the mechanisms by which they work, learning how they can be used safely and effectively, and identifying the right combinations to treat the illnesses that affect us most. We are committed to being the global leader in cannabinoid R&D so that these treatments become a reality.


Steady incremental advances in research and development are vital to positively impact the
way human illness is treated. Cancer poses a particularly difficult challenge. In 1975, fewer than
half of people diagnosed with cancer survived five years. Today, two out of three people
diagnosed with cancer survive at least five years, thanks to advances in oncology drugs and
treatment protocols.

Diverse Biotech’s team is actively pursuing breakthroughs in drug development through
laboratory research and multiple FDA oncology clinical trials that are soon to be enrolling

Our novel cannabinoid formulations are designed to help patients by improving the standard of
care in oncology. Our R&D pipeline addresses many of today’s most significant health
challenges, including cancers of the brain, pancreas, lung, breast, and colon; melanoma; basal
cell carcinoma; squamous cell carcinoma; multiple myeloma; cholangiocarcinoma; and skin
disorders such as actinic keratosis and seborrheic keratosis.


Operating through the FDA New Drug Application process, we continue to focus our research on conditions that represent some of todays most significant health challenges. At Diverse Pharma, this division’s team combines their experience, scientific research and business acumen to do more of what they are passionate about: improving health the well-being of millions of people.

Advancing the Formulas

Our Diverse Pharma division continues to study our novel cannabinoid formulations, with the goal of helping cancer patients around the world.


The cannabis plant (Cannabis sativa L.) contains a large number of pharmacologically active compounds called phytocannabinoids. The most abundant of these compounds are ∆9-tetrahydrocannabinol (THC) and CBD, although the amounts and proportions of the various phytocannabinoids in each plant vary by strain and can be adjusted by breeding.

Cannabinoids have been shown to cause antitumor effects by various mechanisms, including:

  • Induction of cell death by apoptosis1, 2, 3, 4, 5, 6, 7 
  • Inhibition of cancer cell proliferation8, 9, 10
  • Promotion of reactive oxygen species (ROS) activity11
  • Inhibition of tumor angiogenesis12, 13, 14, 15
  • Impede tumor metastasis via inhibition of cell adhesion and invasion16, 17, 18, 19, 20, 21
  • Alteration of the inflammatory microenvironment22, 23

Diverse Biotech’s proprietary cannabinoid formulations are derived from extracts of Cannabis sativa L. plants, i.e., hemp, that have a defined chemical profile and contain consistent levels of phytocannabinoids. Extracts from plants are processed separately to yield pure (>95%) cannabinoid isolates.